Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 479 results found since Jan 2013.
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine
CONCLUSIONS: When patients with cancer were compared with those without cancer, few differences in reported adverse events were noted. Active cancer treatment had little impact on adverse event profiles.PMID:35130494 | DOI:10.6004/jnccn.2021.7113
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 7, 2022 Category: Cancer & Oncology Authors: Rebecca M Shulman David S Weinberg Eric A Ross Karen Ruth Glenn F Rall Anthony J Olszanski James Helstrom Michael J Hall Julia Judd David Y T Chen Robert G Uzzo Timothy P Dougherty Riley Williams Daniel M Geynisman Carolyn Y Fang Richard I Fisher Marshall Source Type: research
Incidental Finding of Moderna COVID-19 Vaccination–Related Axillary Lymphadenopathy on 201Tl Myocardial Perfusion Imaging
We presented here a 71-year-old man with a history of thyroid cancer post total thyroidectomy and 131I ablation and right renal cell carcinoma post right partial nephrectomy. He reported persistent chest tightness and pain after the first dose of the Moderna COVID-19 (mRNA-1273) vaccine. Thus, coronary heart disease was suspected, and the patient was referred for MPI (myocardial perfusion imaging). Focal 201Tl uptake in the left axillary region was found incidentally on MPI, and SPECT/CT revealed enlarged benign-looking lymph nodes. The diagnostic is in favor of reactive hyperplasia after the intramuscular injection of vac...
Source: Clinical Nuclear Medicine - February 2, 2022 Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Uncommon causes of acute appendicitis: foreign bodies in the cecal appendix
Rev Esp Enferm Dig. 2022 Jan 31. doi: 10.17235/reed.2022.8625/2022. Online ahead of print.ABSTRACTA 50-year-old woman with a history of hysterectomy for endometrial cancer in 2015 visited because of abdominal pain for 1 week and fever simultaneous with her third dose of the COVID-19 vaccine. Physical examination revealed a mobile mass in the right iliac fossa, and laboratory testing showed C-reactive protein at 3 mg/dL, with no further changes. Ultrasound results were consistent with an appendiceal inflammatory mass, and a CT scan revealed an appendicolith as likely cause. The patient was subjected to laparoscopy, which fo...
Source: Revista Espanola de Enfermedades Digestivas - January 31, 2022 Category: Gastroenterology Authors: Jose Mar ía Rodríguez Lucas Antonio Jos é Fernández López Francisco Miguel Gonz ález Valverde Mar ía Encarnación Tamayo Rodríguez Antonio Albarrac ín Marín-Blázquez Source Type: research
IJERPH, Vol. 19, Pages 1455: Awareness and Practices Related to Cervical Cancer among Females in Saudi Arabia
This study revealed a low to moderate awareness level toward cervical cancer, pap smear, and HPV vaccine. Thus, awareness campaigns are urgently needed to increase the awareness level for early detection and prevention of the disease.
Source: International Journal of Environmental Research and Public Health - January 27, 2022 Category: Environmental Health Authors: Heba M. Zahid Alma B. Qarah Amal M. Alharbi Arwa E. Alomar Shaimaa A. Almubarak Tags: Article Source Type: research
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of treatments ...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
AbstractTo date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we investigated the frequency of general side effects and immune-related AEs of COVID-19 vaccination. A triage survey was used to collect the following information for patients with metastatic skin cancer: vaccine type, date of receipt of each dose of vaccine, and self-reported side effects. Clinical data were retrieved fr...
Source: Cancer Immunology, Immunotherapy - December 23, 2021 Category: Cancer & Oncology Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
